The primary component of this product is Tirzepatide, carefully selected for its well-documented effectiveness and wide range of applications. Each package contains 1 vial (5mg/vial + 1ml Ampoule ), ensuring precise and consistent dosing to meet various user needs.
DRIADA
1 vial (5mg/vial + 1ml Ampoule )
$11.70
Cashback on this product
Based on 15% cashback rate for 1 items total ($78.00)
Tirzepatide
DRIADA
1 vial (5mg/vial + 1ml Ampoule )
Tirzepatide is an innovative pharmacological agent that represents a significant advancement in the treatment of type 2 diabetes mellitus (T2DM) and obesit. This drug is a dual agonist that targets both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. These incretin hormones are naturally occurring peptides involved in the regulation of glucose homeostasis and energy balance. By simultaneously targeting these pathways, tirzepatide exerts a synergistic effect that enhances its efficacy in managing hyperglycemia and promoting weight loss, distinguishing it from existing therapies that typically target only the GLP-1 receptor.
